Investment funds
There is no better return on an investment than hope.
Oncology
Because if there exists a specialised branch of medicine that has traditionally required large investments, it is oncology. Investments needed to improve the mechanisms for cancer diagnosis, treatment and surgery. A disease in which life expectancy is increasing, but a disease that increasingly affects a greater number of people.
Why invest in this trend?
-
The increase in life expectancy will lead to an increase in cancer cases.In the vast majority of cases, cancer develops with age and, as life expectancy increases, the chances of suffering from this disease increase with it.
-
The development of emerging countries will generate new demands.Investment in health is a fundamental aspect in the economic and social development of countries. Regions that, as they grow, require more medicines and higher quality medical services and from which an increase in demand for oncology solutions is expected. A piece of data: The higher the GDP of a country, the higher its spending on health
-
Greater investment by governments.The saturation of health services throughout the pandemic has made governments aware of the need to gradually but constantly increase investments in health.
-
And the noblest of reasons:Invest in the possibility of a cure and improved treatment for the 40% of the population that, at some point in their lives, is expected to suffer from this disease.
We talk about cancer as a disease, but there are more than 100 different diseases: Solid tumours such as those of the breast, lung, skin or kidney and blood cancers such as lymphomas or leukaemia.
83% of survival improvements in cancer are attributed to the development of new treatments.
-
But the best treatment is still an early diagnosis of the disease.The early detection of cancer is of vital importance for its subsequent treatment. The use of new technologies for early diagnosis, such as liquid biopsy, the development of kits to detect circulating tumour DNA, advanced diagnostic imaging, as well as artificial intelligence have proven to be of great help in the early detection and treatment of cancer patients.
Figures we would prefer not to publish:
-
Cancer is the second cause of death worldwide and the first in many developed countries.
-
The ageing of the world population is expected to cause global deaths due to cancer to increase from 9.5 million to 16.5 million, which is 72% more.
Cancer incidence by age
Sources: National Institute of Health (NIH), World Health Organisation (WHO), Cancer Research UK, *Biomedtracker and Candriam Research
The investment universe is focused on listed companies that offer a significant contribution to the diagnosis and treatment of cancer.
- Diagnosis and research.
- Pharmaceuticals and biotechnology.
- Medical technology.
- Big data and artificial intelligence.
What do the experts think?
The combination of the economic benefits that employing circular practices entails for companies, together with consumers who are more aware of the impact of their habits, is driving the demand for more sustainable products.
Our investment proposal
The value of investment funds1 can fall as well as rise, and you may get back less than you invested.
ES0113573002
BANKINTER PLATEA MEGATENDENCIAS
Medium/High
EUR
10 €
Access your private area to continue arranging the fund.
Go to y account
Call us on 900 816 833 and we'll explain how to arrange this fund.
- SEE ENGLISH SUMMARY OF THE INVESTOR RIGHTS OF THE CANDRIAM ONCOLOGY IMPACT FUND
- SEE SUMMARY IN SPANISH OF THE RIGHTS OF INVESTORS IN THE BANKINTER PLATEA MEGATENDENCIAS FUND
-
Show/Hide legal text1 Investment funds: The key investor information document, prospectus and all other legal documents related to Bankinter's collective investment institutions are available at any of our branches, on the Bankinter website (www.bankinter.com) and on the website of the Spanish National Securities Market Commission (CNMV) (www.cnmv.es).
-
Show/Hide legal textThe Key Investor Information Document and the prospectus are available on the website of the investment managers: Bankinter.com; Candriam | Candriam
More information on this product can be found on the websites of the investment managers: Bankinter.com; Candriam | Candriam -
Show/Hide legal textThis is an advertising communication. Please refer to the UCITS prospectus and key investor information document before making a final investment decision. The fund managers may decide to stop marketing the funds in the situations provided for in applicable legislation, in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.
-
Show/Hide legal textThe Candriam Oncology Impact fund is a sub-fund of Candriam Equities L SICAV. It is authorised in Luxembourg, regulated by the Commissión de Surveillance du Secteur Financier (CSSF) and registered with the CNMV under number 233.
-
Show/Hide legal textThe BANKINTER PLATEA MEGATENDENCIAS fund is a fund from Bankinter Gestión de Activos, S.A., SGIIC authorised in Spain and regulated by the CNMV, with which it is registered as number 5408.
-
Show/Hide legal textThe CIS promotes environmental, social and governance (ESG) criteria under Article 8 of Regulation (EU) 2019/2088 on the disclosure of information related to sustainability in the financial services sector, also known by the English acronym SFDR, and is subject to sustainability risk, as defined in the risk profile. Decisions to invest in this fund must consider all of the characteristics and objectives of the fund.
-
Show/Hide legal textSee information on aspects related to sustainability: Sustainable & Responsible Investments | Candriam; Sustainability Plan | Bankinter Corporate Website.